Covid Vaccine Race

COVID-19 disease severity was mild in individuals in Qatar infected with the Omicron BA.1 and BA.2 sublineages with vaccination and booster doses reducing risks even further, a new study showed.

Valneva’s COVID-19 vaccine candidate, VLA2001, demonstrated superior virus-neutralizing antibodies compared to the AstraZeneca vaccine.

The federal agency's recommendation for both the Moderna and the Pfizer-BioNTech updated bivalent vaccines allows people to get the booster dose this fall.

This Emergency Use Authorization for the Moderna and Pfizer-BioNTech vaccines brings them both one step closer for people to become eligible for these boosters.

AIVITA’s COVID-19 vaccine candidate contains only the subject’s primed immune cells.

A new study found that patients hospitalized with COVID-19 are at significantly higher risk for venous thromboembolism in the ensuing 3 months than are patients hospitalized with influenza.

A study published this week by the American Heart Association found myocarditis was more common after COVID-19 infection than after COVID-19 vaccination.

The Cambridge-MA., company accuses Pfizer and BioNTech of copying patented technology in the development of their COVID-19 vaccine.

Pfizer-BioNTech and Moderna have developed new booster shots optimized for Omicron. They could be approved as soon as Labor Day.

If granted the Emergency Use Authorization (EUA), this vaccine would be available for individuals 18 years and older.

Read this week’s top infectious disease stories you may have missed, including Dr. Anthony Fauci’s announcement.

The companies are requesting the Emergency Use Authorization (EUA) for 30-µg booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and older.

A third dose of mRNA COVID-19 vaccines may allow most immune compromised patients with hematologic cancers to achieve antibody response levels similar to those of healthy adults after a two-dose series.

People who initially received an mRNA vaccine but were boosted with the Janssen vaccine had superior immune responses, the study found.

If it is granted an Emergency Use Authorization (EUA), the vaccine could be used as a booster dose for individuals 18 years and older vaccinated with any of the other available COVID-19 vaccines.

Investigators sought to address the effectiveness of vaccination after COVID-19 recovery.

The booster is designed for immunization against the original wild strain as well as Omicron variant.

The company and its partner, Pfizer, are preparing for the potential launch of 2 variant-adapted bivalent COVID-19 vaccines assuming authorizations from FDA and EMA.

This study looks to identify safety, efficacy of the vaccine in the youngest pediatric populations.

The modified spike protein in this next-generation bivalent candidate is part of the companies' strategy to try and provide vaccines with longer and more durable protection against the virus.

Omicron-specific vaccine boosters are coming, but just how necessary are they?

Clinicians offer insights on a variety of elements surrounding boosters.

As the pandemic enters its third year, fatigue and frustration grow, but there is hope for the future.

He is experiencing mild symptoms and is going to take Paxlovid.

This decision follows votes to allow the vaccine to be indicated for prevention of the virus in adults 18 years and older.

Predicted time to breakthrough infection after mRNA vaccination was significantly longer than the time to breakthrough infection after natural infection or after viral vector vaccination.

The European agency says there have been “a few cases of anaphylaxis.” The label will also include warnings for paraesthesia and hypoaesthesia.

There has been an increase in transmission rates, the release of new White House strategies to address BA.5, and new potential offerings to prevent and treat the virus.

The federal agency says it is indicated as a two-dose primary series for active immunization to prevent the virus in individuals 18 years of age and over.